Compound development

STX100 series

STX100 inhibits an interaction essential in the Homologous Recombination (HR) DNA repair pathway by targeting Rad51.

 We are developing this compound as a monotherapy for specific types of cancers which are dependent on HR. 

STX200 series

STX200 encompasses a class of compounds that functionally disrupt oncogenic KRas, but not WT KRas, interactions with downstream effectors.

These compounds exhibit selective activity for KRas mutants such as KRas(G12D) and KRas(G12V).

Our drug development pipeline

  • Twitter
  • LinkedIn Social Icon

© 2020 by SyntheX

409 Illinois st, San Francisco, CA 94158